BeiGene Gears Up For Cancer Immunology Debut
This article was originally published in PharmAsia News
After entering three drug candidates to clinical stage, securing first round financing and obtaining milestone payments from Merck Serono, BeiGene has eyed unveiling a cancer immunology pipeline and a potential listing on the NASDAQ.
You may also be interested in...
Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal
Pfizer partnered with Germany’s Merck KGAA to develop and commercialize an anti-PD-L1 checkpoint inhibitor in clinical development, paying $850 million upfront to catch up to the competition.
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.